In May 2007, my colleague Kathy Wolski and I published an independent analysis of Avandia in the New England Journal of Medicine (NEJM), showing a statistically significant 43% increase in heart attack.
The paper, which Nissen and Topol wrote with Kathy Wolski, a Cleveland Clinic statistician, combines results from five clinical trials of Pargluva in which the drug was compared to either placebo or other diabetes drugs.